ODC (Ornithine Decarboxylase)-Dependent Putrescine Synthesis Maintains MerTK (MER Tyrosine-Protein Kinase) Expression to Drive Resolution.
Animals
Apoptosis
/ physiology
Atherosclerosis
/ metabolism
Cells, Cultured
Gene Knockout Techniques
Histones
/ metabolism
Inflammation
/ metabolism
Interleukin-10
/ biosynthesis
MAP Kinase Signaling System
Macrophages
/ cytology
Mice
Mice, Knockout
Models, Biological
Ornithine Decarboxylase
/ deficiency
Phagocytosis
/ physiology
Putrescine
/ biosynthesis
c-Mer Tyrosine Kinase
/ genetics
atherosclerosis
histones
inflammation
macrophages
putrescine
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
pubmed:
8
1
2021
medline:
16
3
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
ODC (ornithine decarboxylase)-dependent putrescine synthesis promotes the successive clearance of apoptotic cells (ACs) by macrophages, contributing to inflammation resolution. However, it remains unknown whether ODC is required for other arms of the resolution program. Approach and Results: RNA sequencing of ODC-deficient macrophages exposed to ACs showed increases in mRNAs associated with heightened inflammation and decreases in mRNAs related to resolution and repair compared with WT (wild type) macrophages. In zymosan peritonitis, myeloid ODC deletion led to delayed clearance of neutrophils and a decrease in the proresolving cytokine, IL (interleukin)-10. Nanoparticle-mediated silencing of macrophage ODC in a model of atherosclerosis regression lowered IL-10 expression, decreased efferocytosis, enhanced necrotic core area, and reduced fibrous cap thickness. Mechanistically, ODC deletion lowered basal expression of MerTK (MER tyrosine-protein kinase)-an AC receptor-via a histone methylation-dependent transcriptional mechanism. Owing to lower basal MerTK, subsequent exposure to ACs resulted in lower MerTK-Erk (extracellular signal-regulated kinase) 1/2-dependent IL-10 production. Putrescine treatment of ODC-deficient macrophages restored the expression of both MerTK and AC-induced IL-10. These findings demonstrate that ODC-dependent putrescine synthesis in macrophages maintains a basal level of MerTK expression needed to optimally resolve inflammation upon subsequent AC exposure. Graphic Abstract: A graphic abstract is available for this article.
Identifiants
pubmed: 33406854
doi: 10.1161/ATVBAHA.120.315622
pmc: PMC8034502
mid: NIHMS1658712
doi:
Substances chimiques
Histones
0
IL10 protein, mouse
0
Interleukin-10
130068-27-8
Mertk protein, mouse
EC 2.7.10.1
c-Mer Tyrosine Kinase
EC 2.7.10.1
Ornithine Decarboxylase
EC 4.1.1.17
Putrescine
V10TVZ52E4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e144-e159Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132412
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127464
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007343
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL087123
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL159012
Pays : United States
Références
Cell Metab. 2020 Mar 3;31(3):518-533.e10
pubmed: 32004476
Cell Metab. 2019 Feb 5;29(2):443-456.e5
pubmed: 30595481
Sci Transl Med. 2015 Feb 18;7(275):275ra20
pubmed: 25695999
J Mol Biol. 2015 Oct 23;427(21):3389-406
pubmed: 26156863
Immunity. 2019 May 21;50(5):1149-1162
pubmed: 31117011
Transgenic Res. 1999 Aug;8(4):265-77
pubmed: 10621974
Nature. 1997 Nov 27;390(6658):350-1
pubmed: 9389474
Amino Acids. 2015 Mar;47(3):469-81
pubmed: 25471600
Nucleic Acids Res. 2003 Jan 1;31(1):334-41
pubmed: 12520017
Nat Rev Cancer. 2004 Oct;4(10):781-92
pubmed: 15510159
FASEB J. 2007 Feb;21(2):325-32
pubmed: 17267386
Nat Rev Immunol. 2020 Apr;20(4):254-267
pubmed: 31822793
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
J Immunol. 2005 Mar 1;174(5):3015-23
pubmed: 15728515
Nat Rev Immunol. 2010 Mar;10(3):170-81
pubmed: 20154735
Mol Cell. 2005 Aug 5;19(3):381-91
pubmed: 16061184
Circ Res. 2020 Jul 17;127(3):335-353
pubmed: 32336197
Sci Signal. 2018 Sep 25;11(549):
pubmed: 30254055
J Clin Invest. 1998 Feb 15;101(4):890-8
pubmed: 9466984
Sci Transl Med. 2020 Jul 22;12(553):
pubmed: 32718990
Cell Rep. 2020 Mar 17;30(11):3671-3681.e5
pubmed: 32187540
J Immunol. 1990 May 15;144(10):3877-80
pubmed: 2332635
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):e131-e157
pubmed: 28729366
FASEB J. 2008 Oct;22(10):3595-606
pubmed: 18559988
Immunity. 2018 Oct 16;49(4):666-677.e6
pubmed: 30291029
Mol Med. 2003 Jan-Feb;9(1-2):10-7
pubmed: 12765335
Int J Cancer. 1997 Jan 17;70(2):175-82
pubmed: 9009157
Nat Cell Biol. 2015 Jul;17(7):893-906
pubmed: 26098576
Genome Biol. 2014;15(12):550
pubmed: 25516281
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):563-9
pubmed: 16410462
ACS Nano. 2016 May 24;10(5):5280-92
pubmed: 27100066
J Clin Invest. 2017 Feb 1;127(2):564-568
pubmed: 28067670
Nature. 2016 Apr 14;532(7598):240-244
pubmed: 27049947
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17396-401
pubmed: 21969579
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):922-30
pubmed: 27378395
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Nature. 2016 Aug 4;536(7614):86-90
pubmed: 27437576
J Biol Chem. 2001 Sep 14;276(37):34458-64
pubmed: 11461922
Oncogene. 2008 Apr 10;27(17):2412-21
pubmed: 17968314
Cell. 2017 Oct 5;171(2):331-345.e22
pubmed: 28942921
J Biol Chem. 2019 May 3;294(18):7221-7230
pubmed: 30846565
J Biol Chem. 1991 Apr 5;266(10):6137-41
pubmed: 1848849
FEBS Lett. 2002 Sep 11;527(1-3):223-28
pubmed: 12220664
J Med Chem. 2006 Jan 12;49(1):80-91
pubmed: 16392794
Immunity. 2007 Dec;27(6):952-64
pubmed: 18093541
J Immunol. 2005 Feb 15;174(4):2098-105
pubmed: 15699140
Front Cardiovasc Med. 2018 Jan 08;4:86
pubmed: 29379788
Front Oncol. 2019 Aug 02;9:705
pubmed: 31428579
J Immunol. 2012 Oct 1;189(7):3508-20
pubmed: 22942426
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E751-E760
pubmed: 28096401
Mol Cell. 2007 Feb 9;25(3):473-81
pubmed: 17289593
Nature. 2000 Jan 13;403(6766):199-203
pubmed: 10646605
Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1421-8
pubmed: 18451332
Nat Commun. 2016 Sep 23;7:12859
pubmed: 27659679
Circulation. 2017 Jan 31;135(5):476-489
pubmed: 28137963
Nat Rev Immunol. 2008 May;8(5):349-61
pubmed: 18437155
FASEB J. 2010 Aug;24(8):2869-80
pubmed: 20354139
FASEB J. 2001 Dec;15(14):2730-2
pubmed: 11687507
PLoS One. 2015 Jun 05;10(6):e0128996
pubmed: 26046657
J Anim Sci Biotechnol. 2019 Sep 10;10:69
pubmed: 31516701
Blood. 2008 Nov 15;112(10):4117-27
pubmed: 18779392
J Med Chem. 2006 Nov 16;49(23):6897-907
pubmed: 17154519
Circ J. 2016 Oct 25;80(11):2259-2268
pubmed: 27725526
J Immunol. 2007 Feb 1;178(3):1581-8
pubmed: 17237407
Sci Rep. 2016 Dec 13;6:39111
pubmed: 27958361
Nature. 2011 Aug 21;477(7363):220-4
pubmed: 21857682